The efficacy and safety of peginterferon-α-2a in Korean patients with chronic hepatitis B

A multicenter study conducted in a real clinical setting

Jung Hyun Kwon, Young Seok Kim, Sang Gyune Kim, Jeong Won Jang, Tae Hun Kim, Young Kul Jung, Oh Sang Kwon

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Aims: Genotype C is the principal type of hepatitis B virus (HBV) in Koreans and is associated with poor prognosis for peginterferon ?-2a therapy. The efficacy of and compliance to peginterferon ?-2a therapy were investigated in Koreans with hepatitis B in a real clinical setting. Methods: Hepatitis B patients treated with peginterferon ?-2a from 2008 to 2011 at four university hospitals were consecutively enrolled. Results: Eighty-eight patients were enrolled; 67 were hepatitis B e antigen (HBeAg)-positive. The mean treatment period was 36.1±15.2 weeks. In 26.1% of patients, treatment was discontinued due to insufficient antiviral effects and adverse events. At 24 weeks after treatment, 10/42 (23.8%) HBeAg-positive patients achieved both HBV DNA suppression to <2,000 IU/mL and HBeAg loss/seroconversion. For HBeAg-negative patients, 10/13 (76.9%) achieved HBV DNA suppression to <2,000 IU/mL at 24 weeks after treatment. During the follow-up period, 15 (30.6%) of the 49 patients who achieved HBV DNA suppression to 2,000 IU/mL developed a breakthrough HBV DNA level of >2×106 IU/mL. Conclusions: Peginterferon ?-2a therapy in Koreans with hepatitis B in a real clinical setting resulted in a lower virologic response, as compared to Western individuals, but a favorable durability. There is a need to reduce the high rate of premature discontinuation compared to the controlled studies.

Original languageEnglish
Pages (from-to)197-205
Number of pages9
JournalGut and Liver
Volume7
Issue number2
DOIs
Publication statusPublished - 2013 Mar 1
Externally publishedYes

Fingerprint

Chronic Hepatitis B
Multicenter Studies
Safety
Hepatitis B
Hepatitis B e Antigens
Hepatitis B virus
Therapeutics
Antiviral Agents
Genotype
DNA

Keywords

  • Asian continental ancestry group
  • Chronic hepatitis B
  • Peginterferon

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

The efficacy and safety of peginterferon-α-2a in Korean patients with chronic hepatitis B : A multicenter study conducted in a real clinical setting. / Kwon, Jung Hyun; Kim, Young Seok; Kim, Sang Gyune; Jang, Jeong Won; Kim, Tae Hun; Jung, Young Kul; Kwon, Oh Sang.

In: Gut and Liver, Vol. 7, No. 2, 01.03.2013, p. 197-205.

Research output: Contribution to journalArticle

Kwon, Jung Hyun ; Kim, Young Seok ; Kim, Sang Gyune ; Jang, Jeong Won ; Kim, Tae Hun ; Jung, Young Kul ; Kwon, Oh Sang. / The efficacy and safety of peginterferon-α-2a in Korean patients with chronic hepatitis B : A multicenter study conducted in a real clinical setting. In: Gut and Liver. 2013 ; Vol. 7, No. 2. pp. 197-205.
@article{ba827b5bf3204056a41c1ec31aac4139,
title = "The efficacy and safety of peginterferon-α-2a in Korean patients with chronic hepatitis B: A multicenter study conducted in a real clinical setting",
abstract = "Background/Aims: Genotype C is the principal type of hepatitis B virus (HBV) in Koreans and is associated with poor prognosis for peginterferon ?-2a therapy. The efficacy of and compliance to peginterferon ?-2a therapy were investigated in Koreans with hepatitis B in a real clinical setting. Methods: Hepatitis B patients treated with peginterferon ?-2a from 2008 to 2011 at four university hospitals were consecutively enrolled. Results: Eighty-eight patients were enrolled; 67 were hepatitis B e antigen (HBeAg)-positive. The mean treatment period was 36.1±15.2 weeks. In 26.1{\%} of patients, treatment was discontinued due to insufficient antiviral effects and adverse events. At 24 weeks after treatment, 10/42 (23.8{\%}) HBeAg-positive patients achieved both HBV DNA suppression to <2,000 IU/mL and HBeAg loss/seroconversion. For HBeAg-negative patients, 10/13 (76.9{\%}) achieved HBV DNA suppression to <2,000 IU/mL at 24 weeks after treatment. During the follow-up period, 15 (30.6{\%}) of the 49 patients who achieved HBV DNA suppression to 2,000 IU/mL developed a breakthrough HBV DNA level of >2×106 IU/mL. Conclusions: Peginterferon ?-2a therapy in Koreans with hepatitis B in a real clinical setting resulted in a lower virologic response, as compared to Western individuals, but a favorable durability. There is a need to reduce the high rate of premature discontinuation compared to the controlled studies.",
keywords = "Asian continental ancestry group, Chronic hepatitis B, Peginterferon",
author = "Kwon, {Jung Hyun} and Kim, {Young Seok} and Kim, {Sang Gyune} and Jang, {Jeong Won} and Kim, {Tae Hun} and Jung, {Young Kul} and Kwon, {Oh Sang}",
year = "2013",
month = "3",
day = "1",
doi = "10.5009/gnl.2013.7.2.197",
language = "English",
volume = "7",
pages = "197--205",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "2",

}

TY - JOUR

T1 - The efficacy and safety of peginterferon-α-2a in Korean patients with chronic hepatitis B

T2 - A multicenter study conducted in a real clinical setting

AU - Kwon, Jung Hyun

AU - Kim, Young Seok

AU - Kim, Sang Gyune

AU - Jang, Jeong Won

AU - Kim, Tae Hun

AU - Jung, Young Kul

AU - Kwon, Oh Sang

PY - 2013/3/1

Y1 - 2013/3/1

N2 - Background/Aims: Genotype C is the principal type of hepatitis B virus (HBV) in Koreans and is associated with poor prognosis for peginterferon ?-2a therapy. The efficacy of and compliance to peginterferon ?-2a therapy were investigated in Koreans with hepatitis B in a real clinical setting. Methods: Hepatitis B patients treated with peginterferon ?-2a from 2008 to 2011 at four university hospitals were consecutively enrolled. Results: Eighty-eight patients were enrolled; 67 were hepatitis B e antigen (HBeAg)-positive. The mean treatment period was 36.1±15.2 weeks. In 26.1% of patients, treatment was discontinued due to insufficient antiviral effects and adverse events. At 24 weeks after treatment, 10/42 (23.8%) HBeAg-positive patients achieved both HBV DNA suppression to <2,000 IU/mL and HBeAg loss/seroconversion. For HBeAg-negative patients, 10/13 (76.9%) achieved HBV DNA suppression to <2,000 IU/mL at 24 weeks after treatment. During the follow-up period, 15 (30.6%) of the 49 patients who achieved HBV DNA suppression to 2,000 IU/mL developed a breakthrough HBV DNA level of >2×106 IU/mL. Conclusions: Peginterferon ?-2a therapy in Koreans with hepatitis B in a real clinical setting resulted in a lower virologic response, as compared to Western individuals, but a favorable durability. There is a need to reduce the high rate of premature discontinuation compared to the controlled studies.

AB - Background/Aims: Genotype C is the principal type of hepatitis B virus (HBV) in Koreans and is associated with poor prognosis for peginterferon ?-2a therapy. The efficacy of and compliance to peginterferon ?-2a therapy were investigated in Koreans with hepatitis B in a real clinical setting. Methods: Hepatitis B patients treated with peginterferon ?-2a from 2008 to 2011 at four university hospitals were consecutively enrolled. Results: Eighty-eight patients were enrolled; 67 were hepatitis B e antigen (HBeAg)-positive. The mean treatment period was 36.1±15.2 weeks. In 26.1% of patients, treatment was discontinued due to insufficient antiviral effects and adverse events. At 24 weeks after treatment, 10/42 (23.8%) HBeAg-positive patients achieved both HBV DNA suppression to <2,000 IU/mL and HBeAg loss/seroconversion. For HBeAg-negative patients, 10/13 (76.9%) achieved HBV DNA suppression to <2,000 IU/mL at 24 weeks after treatment. During the follow-up period, 15 (30.6%) of the 49 patients who achieved HBV DNA suppression to 2,000 IU/mL developed a breakthrough HBV DNA level of >2×106 IU/mL. Conclusions: Peginterferon ?-2a therapy in Koreans with hepatitis B in a real clinical setting resulted in a lower virologic response, as compared to Western individuals, but a favorable durability. There is a need to reduce the high rate of premature discontinuation compared to the controlled studies.

KW - Asian continental ancestry group

KW - Chronic hepatitis B

KW - Peginterferon

UR - http://www.scopus.com/inward/record.url?scp=84875113234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875113234&partnerID=8YFLogxK

U2 - 10.5009/gnl.2013.7.2.197

DO - 10.5009/gnl.2013.7.2.197

M3 - Article

VL - 7

SP - 197

EP - 205

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 2

ER -